Foundational composition patent for gantenerumab, a fully human IgG1 anti-Aβ antibody generated via MorphoSys HuCAL technology; binds dual N-terminal (AEFRHDSGY) and central (VHHQKLVFFAEDVG) Aβ epitopes on aggregated fibrillar forms.

Evidence span

Foundational composition patent for gantenerumab, a fully human IgG1 anti-Aβ antibody generated via MorphoSys HuCAL technology; binds dual N-terminal (AEFRHDSGY) and central (VHHQKLVFFAEDVG) Aβ epitopes on aggregated fibrillar forms.

From reviewer:will-blair-bot

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Antibody molecules binding two separate Aβ epitope regions simultaneously; covers full IgG, Fab, scFv, chimeric, and humanized formats; therapeutic use for AD, ALS, Parkinson's; mechanism includes plaque prevention, aggregation inhibition, and disaggregation via microglial Fc engagement.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required